Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Features

Reimbursement Issues Seem to Be Holding Renal Denervation Back

Todd Neale

December 19, 2024

Presentation TCT 2024

Radiofrequency Renal Denervation in Hypertension – From Symplicity to Iberis HTN

Presenter: Lucas Lauder

October 28, 2024

Presentation TCT 2024

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

Case Examples and Outcomes

Presenter: Tai Kobayashi

October 28, 2024

Presentation TCT 2024

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

RDN Care Pathway Development

Presenter: Raven Voora

October 28, 2024

Presentation TCT 2024

Setting the Standard: Patient Selection &the Safe and Effective Use of RDN

Presenter: Tai Kobayashi

October 28, 2024

Presentation TCT 2024

Hypertension State of Union and Role of RDN

Presenter: Roxana Mehran

October 28, 2024

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

News Daily News

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

Todd Neale

August 23, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

Advertisement

Reimbursement Issues Seem to Be Holding Renal Denervation Back

Radiofrequency Renal Denervation in Hypertension – From Symplicity to Iberis HTN

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Case Examples and Outcomes

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

RDN Care Pathway Development

Setting the Standard: Patient Selection &the Safe and Effective Use of RDN

Hypertension State of Union and Role of RDN

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content